GlycoMimetics announced an acquisition agreement with Crescent Biopharma, with the combined company operating as Crescent Biopharma, backed by a $200 million financing, with the transaction closing in Q2 2025. The company will advance Crescent's portfolio, including CR-001, a tetravalent PD-1 x VEGF bispecific antibody with preliminary proof of concept data expected in 2H26.
Cyborg Score Rationale
The Phase 2 analysis of uproleselan did not achieve its primary endpoint in a trial evaluating the drug in combination with chemotherapy versus chemotherapy alone in newly diagnosed AML patients, failing to demonstrate statistically significant improvement in event-free survival. The company executed a strategic pivot via acquisition to access new immunotherapy assets, reflecting prior setbacks in core development programs.
Top Insights
Completed transformational merger with Crescent Biopharma (June 2025); entity now operates as Crescent Biopharma under ticker CBIO
Lead AML program (uproleselan) failed Phase 2 primary endpoint; strategic pivot to solid tumor immunotherapy via Crescent acquisition
Well-capitalized post-merger with $200M financing and runway extended through 2027; CR-001 bispecific antibody is next near-term catalyst (2H 2026)
Significant workforce reduction (~80%) executed; company shifted from drug discovery mode to development-stage biotech
Named Competitors
Fabhalta — Factor D inhibitor for AML
Venetoclax combinations — Standard-of-care AML therapy